Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

Journal of Clinical Immunology

Volumn 36, Issue 6, 2016, Pages 571-582

  Wasserman, Richard L ^a   Melamed, Isaac ^b   Stein, Mark R ^c   Engl, Werner ^d   Sharkhawy, Marlies ^d   Leibl, Heinz ^d   Puck, Jennifer ^e   Rubinstein, Arye ^f   Kobrynski, Lisa ^g   Gupta, Sudhir ^h   Grant, Andrew J ⁱ   Ratnayake, Anoshie ^j   Richmond, Wendell G ^k   Church, Joseph ^l   Yel, Leman ^m   Gelmont, David ⁿ  

^a Allergy/Immunology Research Center of North Texas   (United States)

^b IMMUNOe International Research Center   (United States)

^c Allergy Associates of the Palm Beaches   (United States)

^d Baxalta Innovations GmbH   (Austria)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^j West Coast Clinical Trials LLC   (United States)

^k Allergy and Asthma Physicians   (United States)

^l CHILDREN S HOSPITAL LOS ANGELES   (United States)

^m Baxalta US   (United States)

ⁿ Baxalta US Inc   (United States)

more..

Author keywords

efficacy; primary immunodeficiency; recombinant human hyaluronidase; Subcutaneous IgG replacement; tolerability

Indexed keywords

ANTIBIOTIC AGENT; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RECOMBINANT HYALURONIDASE; TETANUS TOXOID; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ACUTE SINUSITIS; ADULT; AGED; ALLERGIC RHINITIS; ANTIBIOTIC THERAPY; ANTIBODY TITER; ANXIETY; APHTHOUS STOMATITIS; APPLICATION SITE EXCORIATION; ARTHRALGIA; ARTICLE; ASTHENIA; ASTHMA; BACKACHE; BODY MASS; BRONCHITIS; CELLULITIS; CHILD; CHRONIC SINUSITIS; CONSTIPATION; CONTACT DERMATITIS; CONTUSION; COUGHING; DENTAL CARIES; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; ENZYME REPLACEMENT; EPISTAXIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEMORRHOID; HERPETIC STOMATITIS; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; IMMUNE DEFICIENCY; INFLUENZA; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INFECTION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INSOMNIA; LIMB PAIN; LONG TERM CARE; LONG TERM EXPOSURE; LYMPHADENOPATHY; MALE; MIGRAINE; MULTICENTER STUDY; MYALGIA; NAUSEA; NOSE OBSTRUCTION; OROPHARYNX PAIN; PAIN; PATIENT PREFERENCE; PERIPHERAL EDEMA; PERMEABILITY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROCEDURAL SITE REACTION; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; STEADY STATE; SUBSTITUTION THERAPY; SWELLING; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VIRAL GASTROENTERITIS; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VITAMIN D DEFICIENCY; VOMITING; ADOLESCENT; BACTERIAL INFECTION; CLINICAL TRIAL; HOSPITALIZATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; CHILD; FEMALE; HOSPITALIZATION; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84970024436     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-016-0298-x     Document Type: Article

References (36)

1. Gardulf A, Hammarström L. Subcutaneous administration of immunoglobulins. What are the advantages? Clin Immunother. 1996;6(2):108–16.
2. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1–7.
3. Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323–31.
4. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32:1153–64.
5. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Costa-Carvalho BT, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936–42.
6. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474–8.
7. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am. 2008;28:779–802.
8. Moore ML, Quinn JM. Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency. Pediatr Health. 2009;3(3):231–40.
9. Meth MJ, Rosenthal DW, Bonagura VR. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies. Ann Allergy Asthma Immunol. 2010;105:187–8.
10. Borte M, Bernatowska E, Ochs HD, Roifman CM. The Vivaglobin Study Group. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol. 2011;164:357–64.
11. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.
12. Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CI. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency. 1993;4:81–4.
13. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.
14. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immune deficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65–72.
15. Berger M, Murphy E, Riley P, Bergman GE. The VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–63.
16. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158 Suppl 1:51–9.
17. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. The Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265–73.
18. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427–40.
19. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs. 2007;30(5):293–9.
20. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010;26(2):279–88.
21. Allen CH, Etzwiler LS, Miller MK, Maher G, Mace S, Hostetler MA, et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics. 2009;124:e858–67.
22. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med. 2007;10(6):1312–20.
23. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951–7.
24. Geha RS, Notarangelo LD, Casanova J-L, Chapel H, Conley ME, Fischer A, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;20(4):776–94.
25. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2011;2(54):1–26.
26. Rosengren S, Dychter SS, Printz MA, Huang L. Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval, DC Kennard DA, Frost GI, Sugarman BJ, Muchmore DB. Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration. AAPS J. 2015; Epub ahead of print.
27. U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Biologics Evaluation and Research. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. June 2008. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm072130.htm Last accessed on 27 Mar. 2015.
28. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.
29. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. IPINet Investigators. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315–22.
30. Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30:734–45.
31. Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exper Immunol. 2013;173:365–71.
32. Stein MR, Nelson RP, Church JA, Wasserman RL. Borte M, Vermylen C, Bichler J, The IgPro10 in PID study group. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137–44.
33. Moy JN, Scharenberg AM, Stein MR, Suez D, Roberts RL, Levy RJ, et al. Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency diseases. Clin Exp Immunol. 2010;162:510–5.
34. Berger M, Cunningham-Rundles C, Bonilla FA, Melamed I, Bichler J, Zenker O, et al. Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol. 2007;27(5):503–9.
35. Borte M, Pac M, Serban M, Gonzalez-Quevedo T, Grimbacher B, Jolles S, et al. Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol. 2011;31:752–61.
36. Jolles S, Borte M, Nelson Jr RP, Rojavin M, Bexon M, Lawo J-P, et al. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. Clin Immunol. 2014;150:161–9.